Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 10/20 | 0.35 |
| ▸ | CA2 | P00918 | 10/20 | 0.35 |
| ▸ | CA9 | Q16790 | 8/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843768 | 1.00 | FDPS (0.37) | FDPSCA1CA2CA9CA12 | |
| SCHEMBL349256 | 0.94 | FDPS (0.38) | FDPSCA1CA2CA9CA12 | |
| SCHEMBL17506156 | 0.85 | CA1 (0.38) | FDPSCA1CA2CA9CA12 | |
| SCHEMBL11652653 | 0.84 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL6843770 | 0.80 | RECQL (0.43) | FDPSCA1CA2CA9CA12 | |
| SCHEMBL7463706 | 0.80 | RECQL (0.43) | FDPSCA1CA2CA9CA12 | |
| SCHEMBL3600608 | 0.80 | FDPS (0.39) | FDPSCA1CA2CA9CA12 | |
| SCHEMBL1486848 | 0.79 | FDPS (0.41) | FDPSCA1CA2CA9CA12 | |
| Sulfuric Acid SCHEMBL3118006 | 0.78 | FDPS (0.46) | FDPSCA1CA2CA9SMPD1 | |
| SCHEMBL13997141 | 0.77 | CA2 (0.33) | CA1CA2CA9CA7CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177600-B1 | SYNTHESIS OF BENZOTHIAZEPINES | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-05-23 | — | — | EP | claimed |
| US-9834529-B2 | Synthesis of benzothiazepines | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-12-05 | — | — | US | claimed |
| US-20170210717-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GlaxSmithKline Intellectual Propety (No.2) Limited (GB) | 2017-07-27 | — | — | US | claimed |
| EP-3177600-A1 | SYNTHESIS OF BENZOTHIAZEPINES | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-06-14 | — | — | EP | claimed |
| WO-2016020785-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-02-11 | — | — | WO | claimed |
| EP-3177600-B1 | SYNTHESIS OF BENZOTHIAZEPINES | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-05-23 | — | — | EP | disclosed |
| US-9834529-B2 | Synthesis of benzothiazepines | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834529-B2 | Synthesis of benzothiazepines | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170210717-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GlaxSmithKline Intellectual Propety (No.2) Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| US-20170210717-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GlaxSmithKline Intellectual Propety (No.2) Limited (GB) | 2017-07-27 | — | — | US | disclosed |
| EP-3177600-A1 | SYNTHESIS OF BENZOTHIAZEPINES | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020785-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-02-11 | — | — | WO | disclosed |
| EP-0775126-B1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | WELLCOME FOUND (GB) | 2002-10-30 | — | — | EP | disclosed |
| EP-1203769-A1 | Hypolipidemic 1,4-benzothiazepine derivative | THE WELLCOME FOUNDATION LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| US-5910494-A | NOVEL COMPOUNDS THAT REDUCE THE ABSORPTION OF BILE ACIDS FROM THE INTESTINE; FOR PROPHYLAXIS AND TREATMENT OF HYPERLIPIDEMIC CONDITIONS, SUCH AS ATHEROSCLEROSIS | GLAXO WELLCOME INC. (US) | 1999-06-08 | — | — | US | disclosed |
| EP-0775126-A1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996005188-A1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210717-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GABBR1, GABRE, GABBR2 | FDPS 426/4885CA1 2494/4885CA2 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.